DK1345598T3 - Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser - Google Patents
Anvendelsen af rosiglitazon til behandling af psykiatriske lidelserInfo
- Publication number
- DK1345598T3 DK1345598T3 DK01271216T DK01271216T DK1345598T3 DK 1345598 T3 DK1345598 T3 DK 1345598T3 DK 01271216 T DK01271216 T DK 01271216T DK 01271216 T DK01271216 T DK 01271216T DK 1345598 T3 DK1345598 T3 DK 1345598T3
- Authority
- DK
- Denmark
- Prior art keywords
- rosiglitazone
- treatment
- psychiatric disorders
- psychiatric
- disorders
- Prior art date
Links
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title 2
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 229960004586 rosiglitazone Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0030845.2A GB0030845D0 (en) | 2000-12-18 | 2000-12-18 | Novel treatment |
| PCT/GB2001/005488 WO2002049626A2 (en) | 2000-12-18 | 2001-12-12 | The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired pasticity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1345598T3 true DK1345598T3 (da) | 2008-02-04 |
Family
ID=9905313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01271216T DK1345598T3 (da) | 2000-12-18 | 2001-12-12 | Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20040077525A1 (es) |
| EP (2) | EP1911446A3 (es) |
| JP (2) | JP2004518652A (es) |
| AR (1) | AR032001A1 (es) |
| AT (1) | ATE372118T1 (es) |
| AU (1) | AU2002222180A1 (es) |
| DE (1) | DE60130365T2 (es) |
| DK (1) | DK1345598T3 (es) |
| ES (1) | ES2292529T3 (es) |
| GB (1) | GB0030845D0 (es) |
| PE (1) | PE20020601A1 (es) |
| PT (1) | PT1345598E (es) |
| TW (1) | TWI298998B (es) |
| UY (1) | UY27071A1 (es) |
| WO (1) | WO2002049626A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| US20050004179A1 (en) * | 2003-05-22 | 2005-01-06 | Pedersen Ward A. | Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease |
| AU2003254146A1 (en) * | 2003-07-24 | 2005-03-07 | Case Western Reserve University | Methods for the treatment of parkinson's disease |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| RU2445957C2 (ru) * | 2006-03-16 | 2012-03-27 | Метаболик Солюшнз Девелопмент Компани | Аналоги тиазолидиндиона |
| CA2663347A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| ES2830073T3 (es) | 2007-04-11 | 2021-06-02 | Omeros Corp | Composiciones y métodos para la profilaxis y el tratamiento de adicciones |
| KR101767273B1 (ko) | 2009-03-11 | 2017-08-10 | 오메로스 코포레이션 | 중독의 예방 및 치료용 조성물 및 방법 |
| EP2766018A4 (en) * | 2011-10-13 | 2015-02-25 | Univ Case Western Reserve | RXR AGONIST COMPOUNDS AND METHOD THEREFOR |
| MX2015007479A (es) * | 2012-12-11 | 2015-09-04 | Metabolic Solutions Dev Co Llc | Tiazolidindionas ahorradoras de receptores activados proliferadores de peroxisoma (ppar) y combinaciones para el tratamiento de enfermedades neurodegenerativas. |
| US20150359849A1 (en) * | 2013-01-31 | 2015-12-17 | President And Fellows Of Harvard College | Methods of increasing neuronal connectivity and/or treating a neurodegenerative condition |
| WO2016071727A1 (en) | 2014-11-04 | 2016-05-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prevention and the treatment of rapidly progressive glomerulonephritis |
| US12310967B2 (en) | 2017-12-21 | 2025-05-27 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases |
| US12274703B2 (en) | 2017-12-21 | 2025-04-15 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising a dementia |
| GB201805554D0 (en) * | 2018-04-04 | 2018-05-16 | Wren Therapeutics | Therapy for protein misfolding disease |
| US20210228558A1 (en) * | 2018-06-06 | 2021-07-29 | Minoryx Therapeutics S.L. | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts |
| WO2020132378A2 (en) | 2018-12-22 | 2020-06-25 | Gliapharm Sa | Compositions and methods of treatment for neurological disorders comprising depression |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5741803A (en) * | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| JP4473355B2 (ja) * | 1997-11-19 | 2010-06-02 | 武田薬品工業株式会社 | アポトーシス抑制剤 |
| EP1047423B1 (en) * | 1997-11-19 | 2006-05-10 | Takeda Pharmaceutical Company Limited | Novel apoptosis inhibitors |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| DE69942672D1 (de) * | 1998-12-17 | 2010-09-23 | Mindset Biopharmaceuticals Usa | Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns |
| JP2000273040A (ja) * | 1999-01-19 | 2000-10-03 | Sankyo Co Ltd | トログリタゾンを含有するアポトーシス抑制剤 |
| US6204288B1 (en) * | 1999-03-08 | 2001-03-20 | The University Of Mississippi | 1,2-dithiolane derivatives |
| GB9908647D0 (en) * | 1999-04-15 | 1999-06-09 | Smithkline Beecham Plc | Novel compounds |
| AU7995300A (en) * | 1999-10-05 | 2001-05-10 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
-
2000
- 2000-12-18 GB GBGB0030845.2A patent/GB0030845D0/en not_active Ceased
-
2001
- 2001-12-12 WO PCT/GB2001/005488 patent/WO2002049626A2/en not_active Ceased
- 2001-12-12 EP EP07115642A patent/EP1911446A3/en not_active Withdrawn
- 2001-12-12 US US10/450,885 patent/US20040077525A1/en not_active Abandoned
- 2001-12-12 AT AT01271216T patent/ATE372118T1/de not_active IP Right Cessation
- 2001-12-12 JP JP2002550968A patent/JP2004518652A/ja active Pending
- 2001-12-12 DK DK01271216T patent/DK1345598T3/da active
- 2001-12-12 AU AU2002222180A patent/AU2002222180A1/en not_active Abandoned
- 2001-12-12 ES ES01271216T patent/ES2292529T3/es not_active Expired - Lifetime
- 2001-12-12 EP EP01271216A patent/EP1345598B1/en not_active Expired - Lifetime
- 2001-12-12 PT PT01271216T patent/PT1345598E/pt unknown
- 2001-12-12 DE DE60130365T patent/DE60130365T2/de not_active Expired - Lifetime
- 2001-12-14 PE PE2001001256A patent/PE20020601A1/es not_active Application Discontinuation
- 2001-12-14 UY UY27071A patent/UY27071A1/es not_active Application Discontinuation
- 2001-12-17 TW TW090131174A patent/TWI298998B/zh not_active IP Right Cessation
- 2001-12-18 AR ARP010105872A patent/AR032001A1/es unknown
-
2007
- 2007-06-13 US US11/762,220 patent/US20070238757A1/en not_active Abandoned
-
2008
- 2008-06-05 JP JP2008148304A patent/JP2008260777A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2292529T3 (es) | 2008-03-16 |
| ATE372118T1 (de) | 2007-09-15 |
| JP2004518652A (ja) | 2004-06-24 |
| PT1345598E (pt) | 2007-12-06 |
| AR032001A1 (es) | 2003-10-22 |
| UY27071A1 (es) | 2002-07-31 |
| EP1911446A2 (en) | 2008-04-16 |
| US20070238757A1 (en) | 2007-10-11 |
| EP1345598A2 (en) | 2003-09-24 |
| DE60130365D1 (de) | 2007-10-18 |
| EP1345598B1 (en) | 2007-09-05 |
| TWI298998B (en) | 2008-07-21 |
| US20040077525A1 (en) | 2004-04-22 |
| EP1911446A3 (en) | 2008-09-24 |
| WO2002049626A3 (en) | 2002-10-17 |
| DE60130365T2 (de) | 2008-05-29 |
| WO2002049626A2 (en) | 2002-06-27 |
| AU2002222180A1 (en) | 2002-07-01 |
| GB0030845D0 (en) | 2001-01-31 |
| PE20020601A1 (es) | 2002-09-22 |
| JP2008260777A (ja) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1345598T3 (da) | Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser | |
| DK1343773T3 (da) | Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser | |
| DK1047428T3 (da) | Anvendelse af morpholinol til behandlingen af seksualforstyrrelser | |
| DK1259512T3 (da) | Pteridinforbindelser til behandling af psoreasis | |
| DK3167872T3 (da) | Fremgangsmåder til behandling af inflammationsmedierede tilstande i øjet | |
| DK1063990T3 (da) | Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser | |
| DK1620437T3 (da) | 5,7-diaminopyrazolo-4,3-d-pyrimidiner, der er anvendelige til behandling af hypertension | |
| DK1575597T3 (da) | Anvendelse af rimexolon til behandling af öjentörhed | |
| DK1562932T3 (da) | 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter | |
| AR027945A1 (es) | Uso de pramipexol en el tratamiento de transtornos de adiccion | |
| DK1231920T3 (da) | Anvendelse af epinastin til behandling af allergisk rhinitis/conjunctivitis | |
| EE200200571A (et) | Hüdroksüfenüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks | |
| DK1176964T3 (da) | Brug af ET743 til behandling af cancer | |
| DK2189162T3 (da) | Fremgangsmåder til behandling af cellulære proliferative forstyrrelser | |
| DK1392318T3 (da) | 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse | |
| NO20032122L (no) | Forbedret behandling | |
| DK1326628T3 (da) | Kemokinmutanter til behandling af dissemineret sklerose | |
| EE200200577A (et) | Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks | |
| EE200200511A (et) | Hüdroksüfenüülpiperasinüülmetüülbensamiidi derivaadid valu raviks | |
| DK1257278T3 (da) | Anvendelse af mirtazapin til behandling af sövnforstyrrelser | |
| NO20030978D0 (no) | Behandling av diuresedysfunksjon | |
| DK1268482T3 (da) | Pyranoindoler til behandling af glaukom | |
| DK1468686T3 (da) | S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser | |
| DK1461042T3 (da) | Anvendelse af desoxypeganin til behandling af klinisk depression | |
| NO20030717L (no) | Forbindelser for behandling av avhengighetsforstyrrelser |